黑色素瘤由于轉(zhuǎn)移性強(qiáng)，成為皮膚癌中死亡率最高的惡性腫瘤之一，目前沒(méi)有有效的治療方法。凝血酶蛋白酶激活受體-1（PAR-1）在黑色素瘤的發(fā)病過(guò)程中起到重要作用，PAR-1通過(guò)激活腫瘤細(xì)胞黏附和侵襲以及新生血管因子生成促進(jìn)黑色素瘤轉(zhuǎn)移。PAR-1有望成為治療轉(zhuǎn)移性黑色素瘤藥物新靶點(diǎn)。

Melanoma remains as the deadliest form of skin cancer with limited and inefficient treatment options available for patients with metastatic disease. The thrombin receptor, Protease Activated Receptor-1, has been considered to play an important role in the progression of human melanoma. PAR-1 is known to activate adhesive, invasive and angiogenic factors to promote melanoma metastasis. This review is about the advance in the research of PAR-1as a potential target of metastatic melanoma.

國(guó)家重大新藥創(chuàng)制專項(xiàng)（2011ZX09401-009）；天津市科技支撐計(jì)劃重點(diǎn)項(xiàng)目（10ZCKFSH01300）